Literature DB >> 26742873

Short-term results of platelet-rich plasma as adjuvant to 23-G vitrectomy in the treatment of high myopic macular holes.

Marta S Figueroa1, Andrea Govetto1, Pablo de Arriba-Palomero1.   

Abstract

PURPOSE: To investigate the short-term safety and efficacy of autologous platelet-rich plasma (a-PRP) as adjuvant to pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling in the treatment of highly myopic macular holes (MH).
METHODS: This was a prospective, nonrandomized interventional case series. Patients with MH associated with high myopia, with or without previous PPV, were included. All patients underwent 23-G PPV with the use of a-PRP. Anatomical and functional results of surgery were recorded.
RESULTS: We included 7 eyes of 6 patients with highly myopic MH. Primary anatomical success was achieved in 7 out of 7 eyes. Mean best-corrected visual acuity improved by more than 1 line from baseline (0.66 ± 0.36 LogMAR) to final visit (0.52 ± 0.25 logMAR), but with no statistically significant difference (p = 0.246, Wilcoxon test). No surgical-related complications were noticed.
CONCLUSIONS: The use of a-PRP as adjuvant to PPV with ILM peeling is effective in the treatment of highly myopic MH. This approach may represent a valid alternative to the inverted ILM flap technique, with comparable visual and anatomical results and the advantage of a simpler procedure. Further studies are necessary to confirm its usefulness in the management of high myopic MH.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26742873     DOI: 10.5301/ejo.5000729

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  8 in total

1.  Surgical treatment of macular holes with and without the use of autologous platelet-rich plasma.

Authors:  Alexander A Shpak; Dmitry O Shkvorchenko; Eugenia A Krupina
Journal:  Int Ophthalmol       Date:  2021-01-03       Impact factor: 2.031

2.  Visual Loss after Platelet-rich Plasma Injection into the Face.

Authors:  Emely Z Karam; Alexander Gan; Rafael Muci Mendoza; Edwing Martinez; Evlyn Perez
Journal:  Neuroophthalmology       Date:  2020-03-26

3.  Quantification of Growth Factors and Fibronectin in Diverse Preparations of Platelet-Rich Plasma for the Treatment of Ocular Surface Disorders (E-PRP).

Authors:  Alejandra E Rodriguez; Sandra Gisbert; Antonio Palazón; Jorge L Alio
Journal:  Transl Vis Sci Technol       Date:  2020-05-21       Impact factor: 3.283

4.  Plasma Rich in Growth Factors in Macular Hole Surgery.

Authors:  Ronald M Sánchez-Ávila; Carlos A Robayo-Esper; Eva Villota-Deleu; Álvaro Fernández-Vega Sanz; Álvaro Fernández-Vega González; Borja de la Sen-Corcuera; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Clin Pract       Date:  2022-01-10

Review 5.  Vitrectomy in high myopia: a narrative review.

Authors:  Michele Coppola; Alessandro Rabiolo; Maria Vittoria Cicinelli; Giuseppe Querques; Francesco Bandello
Journal:  Int J Retina Vitreous       Date:  2017-10-02

6.  Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer.

Authors:  Dominika Wróbel-Dudzińska; Jorge Alio; Alejandra Rodriguez; Ewa Suchodoła-Ratajewicz; Ewa Kosior-Jarecka; Beata Rymgayłło-Jankowska; Agnieszka Ćwiklińska-Haszcz; Tomasz Żarnowski
Journal:  J Ophthalmol       Date:  2018-06-20       Impact factor: 1.909

7.  Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors.

Authors:  Ronald M Sánchez-Ávila; Álvaro Fernández-Vega González; Álvaro Fernández-Vega Sanz; Jesús Merayo-Lloves
Journal:  Int Med Case Rep J       Date:  2019-07-12

8.  Autologous Platelet-Rich Fibrin in the Treatment of Refractory Macular Holes.

Authors:  Arif Koytak; Fadime Nuhoglu; Havvanur Bayraktar; Rukiye Ercan; Hakan Ozdemir
Journal:  Case Rep Ophthalmol Med       Date:  2019-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.